封面
市場調查報告書
商品編碼
1840738

持續皮下胰島素輸注市場(按產品類型、胰島素類型、年齡層和最終用戶)—2025-2032 年全球預測

Continuous Subcutaneous Insulin Infusion Market by Product Type, Insulin Type, Age Group, End User - Global Forecast 2025-2032

出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年持續皮下胰島素輸注市場將成長至 78.4 億美元,複合年成長率為 12.51%。

主要市場統計數據
基準年2024年 30.5億美元
預計2025年 34.3億美元
預測年份:2032年 78.4億美元
複合年成長率(%) 12.51%

不斷發展的臨床重點和技術正在將長效胰島素轉變為以患者為中心的互聯治療解決方案

在技​​術創新和護理模式轉變的推動下,持續皮下胰島素輸注已從一種小眾臨床干預手段發展成為糖尿病治療的核心方法。現代系統優先考慮以患者為中心的特性,例如易於使用、與血糖監測工具整合以及符合人體工學的設計。隨著臨床醫生重視個人化血糖管理,設備開發商正致力於開發先進的輸送機制、直覺的使用者介面以及支援遠端監控和遠端醫療工作流程的連接功能。

臨床指南日益認可泵療法在改善特定患者群體血糖穩定性方面的作用,而支付觀點正在逐漸接受將其與改善預後和減少急性併發症聯繫起來的證據。同時,監管框架日趨完善,以適應硬體和軟體的迭代改進,使製造商無需重新設計整個設備平台即可推出增強功能。這些發展正在推動產品更新和軟體主導功能的持續增加。

同時,患者的期望正轉向侵入性更低、更能適應多樣化生活方式的設備。這導致設計重點轉向更小的尺寸、低調的佩戴體驗和更簡單的維護。同時,數據分析和互通性已成為差異化因素,使看護者和護理團隊能夠解讀縱向血糖數據並最佳化治療方案。這些因素共同構成了一個競爭格局,臨床有效性、使用者體驗和系統連結性將決定最終的競爭格局。

新的數位整合、自適應控制演算法和供應鏈現代化正在迅速改變胰島素幫浦治療和護理服務模式。

持續皮下胰島素輸注領域近期的轉型變革反映了數位健康、設備小型化和一體化照護模式的融合,這些因素共同重塑了人們對治療的期望。感測器精確度的提升和演算法的複雜度的提升,使得更聰明的胰島素給藥決策能夠適應現實世界中的波動,例如活動、飲食和壓力。因此,產品藍圖優先考慮閉合迴路相容性、自適應控制策略和安全資料交換,以支援縱向護理管理。

同時,製造和供應鏈策略也在不斷發展,以適應電子和軟體日益融合的趨勢,鼓勵現有設備製造商、半導體供應商和軟體專家之間建立合作夥伴關係。這一趨勢正在加快複雜組件的上市時間,並推動成本和採購方面的創新。監管機構正在透過完善軟體驗證和網路安全指南來應對這項挑戰,以確保安全,同時又不會過度阻礙迭代創新。

同時,報銷模式和醫療服務框架正在逐步調整,以支持居家慢性病管理,鼓勵醫療服務提供者開立能夠進行遠端監控並減少住院治療的設備。患者倡導和教育舉措透過揭開設備使用的神秘面紗並強調其對生活品質的益處,進一步推動了設備的採用。這些轉變共同創造了一個充滿活力的環境,在這個環境中,跨部門整合、證據生成和以使用者為中心的設計將決定長期的成功。

2025 年貿易政策的變化將迫使胰島素供應利益相關人員重新設計敏捷的供應鏈、採取關稅減免策略並採取策略性商業性應對措施

2025年關稅和貿易政策調整的訂定,對持續皮下胰島素輸注領域的製造商、經銷商和醫療保健提供者而言,具有明顯的營運和戰略影響。採購團隊必須重新評估籌資策略,以降低不斷上升的到岸成本和潛在的前置作業時間波動。為此,企業正在評估替代製造佈局,考慮近岸外包零件,並重新協商供應商契約,以分攤供應鏈各層級的關稅風險。

除了採購之外,監管和合規部門正在重新調整文件和關稅分類,以確保準確的關稅處理,並在適用的情況下利用現有的優惠貿易計劃。擁有模組化供應鏈和多元化供應商資源的公司表現出更強的韌性,而那些依賴少數海外供應商的公司更容易受到價格波動的影響。因此,策略規劃現在融入了情境模型,以考慮關稅波動對生產計劃和客戶定價的營運影響。

商業團隊面臨的挑戰是,如何在需求敏感度下降的風險與成本吸收之間取得平衡,同時市場進入和可負擔性。作為過渡策略,相關人員將採取有針對性的成本最佳化措施、漸進式價格調整和增強服務交付,以維護其價值提案。簡而言之,貿易政策的轉變凸顯了敏捷的供應鏈設計、主動與監管機構的合作以及策略性商業規劃的重要性,以保持連續性和競爭力。

產品架構、胰島素配方、患者人口統計和醫療保健環境等多方面細分揭示了差異化的採用促進因素和設計需求

嚴格的細分視角揭示了產品設計、胰島素配方、患者人口統計和護理環境如何影響持續輸註解決方案的採用和使用者體驗。按產品類型分析時,傳統系統和基於貼片的設備之間的差異會影響臨床適用性和患者偏好。傳統選項進一步分為電子泵和機械泵,電子主導平台提供可程式設計的輸送模式、連接性和先進的安全聯鎖裝置,而機械泵則強調針對特定用例的簡單性和耐用性。關於胰島素類型,速效類似物、常規胰島素和短效製劑之間的選擇會影響動態特徵和給藥演算法,從而為設備編程和臨床滴定策略提供資訊。

年齡細分凸顯了成人、老年人和兒童群體的不同需求。成人通常優先考慮生活方式的兼容性和個性化的連接性;老年人群體需要簡化的界面和強大的安全功能,以減輕認知和靈活性的限制;兒科護理需要高度適應性的劑量範圍、看護者控制能力和教育支持。最後,門診護理、居家醫療和醫院環境中的最終用戶觀點揭示了不同的採購促進因素和營運要求。門診環境優先考慮門診病人管理的便攜性和數據共用;居家醫療優先考慮易用性和長期依從性支持;醫院環境優先考慮與電子健康記錄的互通性、無菌輸送通訊協定和急性血糖控制的可靠性。這種細分反映在產品開發、臨床定位和商業化策略中,將技術能力與不同的現實世界需求相匹配。

美洲、歐洲、中東和非洲以及亞太地區的差異化將需要監管、報銷和商業化方法

區域動態對持續輸注技術的採用途徑、報銷架構和基礎設施準備有重大影響。在美洲,醫療保健系統和付款人模式正在推動不同的採用場景,其中,整合護理網路和糖尿病管理項目中的先進採用優先考慮互聯解決方案。因此,製造商將調整其臨床參與和銷售策略,以適應區域報銷政策和專家培訓計劃。

歐洲、中東和非洲地區法規環境差異巨大,醫療保健服務可近性參差不齊,既帶來了挑戰,也帶來了機會。一些歐洲市場強調嚴格的臨床證據和數據隱私合規性,而其他市場則提供與公共衛生計劃和基礎設施投資相關的成長機會。因此,製造商必須採用差異化的打入市場策略,尊重當地監管要求,並利用合作管道進行臨床醫生教育。

亞太地區是一個複雜的區域,快速的都市化、不斷擴張的私人醫療服務以及多元化的法律規範共同作用,這些框架鼓勵城市地區採用創新技術,而都市區的醫療可及性仍是其戰略考量。在所有地區,供應鏈的可靠性、本地監管的協調性以及符合當地文化的患者教育計畫將決定創新技術的採用速度。因此,區域策略必須整合在地化的價值提案、在地相關人員的參與以及靈活的商業模式,以有效應對不同的醫療保健格局。

競爭格局由傳統設備製造商、軟體優先的參與企業和結果主導的服務模式決定,這些模式正在重新定義整個治療生命週期的價值

競爭態勢反映出老牌醫療設備製造商、新興技術參與企業和專業組件供應商的整合,他們攜手合作,共同提升持續輸注能力。現有企業利用深厚的臨床關係、監管經驗和廣泛的分銷網路來維持其市場地位,而新參與企業則傾向於專注於軟體創新、使用者體驗和利基產品外形規格,以接觸特定的患者群體。器械製造商和數位健康供應商之間的策略聯盟加速了能力的整合,尤其是在閉合迴路相容性和數據分析服務方面。

隨著相關人員尋求保護差異化特性,同時實現可控的互通性,與輸液演算法、感測器互通性和網路安全相關的智慧財產權投資已成為戰略重點。同時,服務導向的經營模式(例如捆綁遠端監控訂閱的設備以及整合的培訓和依從性計劃)正日益普及,創造了經常性收益流並增強了病人參與。採購和醫院採購團隊擴大將總體擁有成本與臨床結果一起評估,鼓勵供應商透過真實世界證據和上市後研究來證明其長期價值。

展望未來,競爭優勢將在於那些能夠兼具敏捷的監管、強大的品質和交付體系,以及清晰的產品服務策略,從而在整個治療週期內為臨床醫生和患者提供支援的機構。能夠透過與付款人、醫療服務提供者和患者組織合作,將技術優勢與可衡量的醫療改進相結合的供應商,將進一步脫穎而出。

優先考慮互通性、供應多樣性、現實世界證據和人性化的設計,以增強彈性並加速整個醫療環境中的採用

為了保持永續性並加速應用,產業領導者應優先制定策略議程,將產品創新與臨床整合、供應鏈彈性和付款人參與度相結合。首先,投資可互通的平台和檢驗的演算法,以實現與血糖監測系統和電子健康記錄進行有意義的數據交換。其次,實現製造和籌資策略的多元化,以減少貿易政策波動和零件短缺的風險,同時縮短中斷情況下的恢復時間。

第三,我們將建立一個超越對照試驗、涵蓋真實世界臨床試驗、健康經濟學分析和病人報告結果的證據產生項目。第四,我們將透過提供靈活的購買選項、服務包和臨床醫生培訓,使我們的商業模式與當地支付方情況和最終用戶需求一致,以降低應用門檻。第五,我們將融入人性化的設計原則,以滿足不同年齡層患者的認知、感官和生活方式需求,從而提高依從性和滿意度。

最後,在臨床醫生、付款人、病患權益組織和技術合作夥伴之間建立多方相關人員夥伴關係,共同打造兼顧臨床有效性和實際操作的解決方案。透過實施這種多管齊下的策略,產業領導者可以增強韌性,創造差異化價值,並實現患者和護理團隊的共同改善。

透明的混合方法研究框架,結合相關人員訪談、臨床文獻綜合和供應鏈分析,以產生可操作的設備和商業性見解

調查方法整合了定性和定量分析,以確保全面洞察設備性能、相關人員的觀點和營運限制。主要研究包括對臨床醫生、採購負責人和患者權益倡導者的結構化訪談,以了解設備可用性、臨床工作流程整合以及與依從性相關的現實挑戰的真實體驗。這些訪談產生了主題分析,重點突出了連結性、劑量靈活性和看護者支持的通用痛點和機會領域。

二次研究綜合了已發表的監管指南、臨床文獻和技術標準,為產品設計和核准提供見解。在適用的情況下,技術白皮書和同行評審的臨床研究支援演算法方法和安全評估。我們利用貿易流量數據、採購出版物和供應商資訊披露資訊,分析了供應鏈和貿易政策的影響,從而對營運漏洞和緩解策略形成了切合實際的認知。

最後,對一手資料和二手資料進行了交叉檢驗,以增強專題研究結果和建議的可信度。本調查方法強調透明度、可複製性和相關人員的相關性,同時考慮到地區差異和不斷變化的監管預期,並支持為產品開發、商業化和策略規劃提供可行的結論。

結合互通技術、操作靈活性和有針對性的證據產生的整合策略將決定輸液治療的長期成功

持續皮下胰島素輸注療法正處於曲折點,技術成熟度、醫療模式的轉變以及全球政策動態既帶來了希望,也帶來了複雜性。集強大的安全工程、無縫的數據整合和人性化的可用性於一體的設備將更有效地滿足臨床醫生和患者的期望。同時,供應鏈的敏捷性和監管預見性對於在不斷變化的貿易和合規環境中應對患者用藥需求至關重要。

設備外形規格、胰島素藥理學、患者年齡相關需求以及護理環境要求之間的相互作用,凸顯了細緻的產品系列和有針對性的臨床參與的重要性。此外,競爭優勢將有利於那些能夠將技術差異化轉化為檢驗的臨床和經濟效益的組織。總而言之,採用整合策略的相關人員,將互通技術、多元化企業發展、強力的證據生成以及針對每個地區的客製化方法相結合,將最有可能在糖尿病管理方面取得顯著進展,並在動態治療環境中保持長期成長。

目錄

第1章:前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將連續血糖監測數據與先進的胰島素幫浦演算法結合,可以在混合封閉回路型系統中預測胰島素劑量調整。
  • 開發具有智慧型手機連接和遠端患者監護的無管貼片幫浦,以提高依從性
  • 採用與胰島素幫浦療法相容的超速效胰島素製劑來改善餐後血糖控制
  • 根據即時生活方式數據實施個人化胰島素劑量的人工智慧和機器學習模型
  • 擴大報銷框架和數位健康生態系統,以支援遠端醫療啟動和管理胰島素幫浦治療
  • 製藥和醫療設備製造商合作開發可互通的封閉回路型胰島素輸送解決方案
  • 針對小兒患者,簡化使用者介面和可自訂設定的兒科胰島素幫浦系統需求激增
  • 引入可延長配戴時間的一次性貼片幫浦系統,以減輕使用者的設備維護負擔

第6章:2025年美國關稅的累積影響

第7章:人工智慧的累積影響,2025年

8. 持續皮下胰島素輸注市場(依產品類型)

  • 傳統的
    • 電子底座幫浦
    • 機械幫浦
  • 修補

9. 持續皮下胰島素輸注市場(依胰島素類型)

  • 速效類似物
  • 常規胰島素
  • 短效

第 10 章。按年齡層別分類的持續皮下胰島素輸注市場

  • 成人
  • 老年人
  • 孩子們

第 11 章。 持續皮下胰島素輸注市場(依最終用戶)

  • 門診治療
  • 居家護理
  • 醫院

12. 持續性皮下胰島素輸注市場(按地區)

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章持續皮下胰島素輸注市場(依類別)

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 持續皮下胰島素輸注市場(依國家)

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic PLC
    • Insulet Corporation
    • Tandem Diabetes Care, Inc.
    • Roche Diabetes Care AG
    • Ypsomed AG
    • Sooil Development Co., Ltd.
    • Medtrum Technologies, Inc.
    • Bigfoot Biomedical, Inc.
    • B. Braun SE
    • Baxter International, Inc.
    • Becton, Dickinson and Company
    • MicroPort Scientific Corporation
Product Code: MRR-A339DAEFA756

The Continuous Subcutaneous Insulin Infusion Market is projected to grow by USD 7.84 billion at a CAGR of 12.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.43 billion
Forecast Year [2032] USD 7.84 billion
CAGR (%) 12.51%

How evolving clinical priorities and technology convergence are reshaping continuous insulin delivery toward patient-centered, connected therapy solutions

Continuous subcutaneous insulin infusion has evolved from a niche clinical intervention to a central modality in diabetes care, driven by both technological innovation and shifting care paradigms. Modern systems prioritize patient-centric features such as usability, integration with glucose monitoring tools, and ergonomic design. As clinicians emphasize personalized glycemic management, device developers respond with refined delivery mechanisms, intuitive user interfaces, and connectivity that supports remote monitoring and telehealth workflows.

Clinical guidelines increasingly recognize the role of pump therapy in improving glycemic stability for selected patient populations, and payer perspectives are adapting to evidence that links improved outcomes with reduced acute complications. Meanwhile, regulatory pathways have matured to accommodate iterative improvements in hardware and software, which allows manufacturers to deploy enhancements without reworking entire device platforms. These developments encourage a steady cadence of product refreshes and software-driven feature additions.

At the same time, patient expectations have shifted toward minimally intrusive devices that fit diverse lifestyles. Consequently, design emphasis has moved toward smaller form factors, discreet wearability, and simplified maintenance. In parallel, data analytics and interoperability features have become differentiators, enabling caregivers and care teams to interpret longitudinal glucose data and optimize therapy. Taken together, these forces are shaping a landscape where clinical effectiveness, user experience, and system connectivity determine competitive positioning.

Emerging digital integration, adaptive control algorithms, and supply chain modernization are rapidly transforming insulin pump therapy and care delivery models

Recent transformative shifts in continuous subcutaneous insulin infusion reflect a convergence of digital health, device miniaturization, and integrated care models that together redefine therapeutic expectations. Advances in sensor accuracy and algorithm sophistication enable smarter insulin delivery decisions that adapt to real-world variability in activity, meals, and stress. As a result, product roadmaps prioritize closed-loop compatibility, adaptive control strategies, and secure data exchange to support longitudinal care management.

Simultaneously, manufacturing and supply chain strategies are evolving to accommodate higher integration of electronics and software, prompting collaborative partnerships between established device manufacturers, semiconductor suppliers, and software specialists. This trend reduces time to market for complex assemblies and drives innovation in cost and component sourcing. Regulatory bodies are responding by refining guidance on software validation and cybersecurity to ensure safety without unduly hindering iterative innovation.

In parallel, reimbursement models and care delivery frameworks are gradually aligning to support home-based chronic disease management, encouraging providers to prescribe devices that enable remote monitoring and reduce inpatient utilization. Patient advocacy and education initiatives further spur adoption by demystifying device use and emphasizing quality-of-life benefits. Collectively, these shifts create a dynamic environment where cross-functional integration, evidence generation, and user-centered design determine long-term success.

Trade policy shifts in 2025 compel agile supply chain redesign, tariff mitigation tactics, and strategic commercial responses across insulin delivery stakeholders

The introduction of tariffs and adjusted trade policies in 2025 has clear operational and strategic implications for manufacturers, distributors, and healthcare providers involved in continuous subcutaneous insulin infusion. Procurement teams must reassess sourcing strategies to mitigate increased landed costs and potential lead-time variability. In response, firms evaluate alternative manufacturing footprints, consider nearshoring components, and renegotiate supplier contracts to distribute tariff exposure across supply chain tiers.

Beyond procurement, regulatory and compliance functions are recalibrating documentation and customs classifications to ensure accurate duty treatment and to exploit available preferential trade programs where applicable. Firms with modular supply chains and diversified supplier pools demonstrate greater resilience, while those reliant on a narrow set of overseas suppliers face heightened vulnerability to price volatility. Consequently, strategic planning now integrates scenario modeling that examines the operational implications of tariff fluctuations on production schedules and customer pricing.

Commercial teams confront the challenge of preserving market access and affordability for patients, balancing cost absorption against the risk of reduced demand sensitivity. As transitional strategies, stakeholders pursue targeted cost optimization initiatives, incremental pricing adjustments, and enhanced service offerings to sustain value propositions. In short, trade policy shifts underscore the importance of agile supply chain design, proactive regulatory engagement, and strategic commercial planning to maintain continuity and competitiveness.

Multi-dimensional segmentation across product architecture, insulin formulations, patient age cohorts, and care settings reveals differentiated adoption drivers and design imperatives

A rigorous segmentation lens clarifies how product design, insulin formulations, patient demographics, and care settings shape adoption and user experience across continuous infusion solutions. When analyzed by product type, distinctions between Conventional systems and Patch-based devices influence clinical suitability and patient preference; Conventional options further differentiate into electronics-based pumps and mechanical pumps, with electronics-driven platforms offering programmable delivery patterns, connectivity, and advanced safety interlocks while mechanical pumps emphasize simplicity and durability for specific use cases. Regarding insulin type, choices among rapid-acting analogs, regular insulin, and short-acting formulations affect pharmacodynamic profiles and dosing algorithms, informing both device programming and clinical titration strategies.

Age group segmentation highlights divergent needs across adult, geriatric, and pediatric cohorts: adults often prioritize lifestyle compatibility and discrete connectivity, geriatric populations require simplified interfaces and robust safety features to mitigate cognitive or dexterity limitations, and pediatric care demands highly adaptable dosing ranges, caregiver control features, and educational supports. Finally, end-user perspectives spanning ambulatory care, homecare, and hospitals reveal distinct procurement drivers and operational requirements; ambulatory settings emphasize portability and data sharing for outpatient management, homecare focuses on ease of use and long-term adherence supports, and hospital environments prioritize interoperability with electronic health records, sterile supply protocols, and acute glycemic control reliability. Together, these segmentation dimensions inform product development, clinical positioning, and commercialization strategies that align technological capabilities with diverse real-world needs.

Regional differentiation across the Americas, Europe Middle East & Africa, and Asia-Pacific demands tailored regulatory, reimbursement, and commercialization approaches

Regional dynamics exert a powerful influence on adoption pathways, reimbursement frameworks, and infrastructure readiness for continuous infusion technologies. In the Americas, healthcare systems and payer models create varied uptake scenarios, with pockets of advanced adoption where integrated care networks and diabetes management programs prioritize connected solutions. Consequently, manufacturers orient clinical engagement and distribution strategies to align with regional reimbursement policies and specialist training programs.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse healthcare access levels create both challenges and opportunities. Some European markets emphasize rigorous clinical evidence and data privacy compliance, while markets across the Middle East and Africa offer growth opportunities tied to public health initiatives and infrastructure investments. Manufacturers must therefore adopt differentiated market-entry strategies that respect local regulatory requirements and leverage partnership channels for clinician education.

Asia-Pacific presents a complex mix of rapid urbanization, expanding private healthcare provision, and varied regulatory frameworks that encourage innovation adoption in urban centers while rural access remains a strategic consideration. Across all regions, supply chain reliability, local regulatory harmonization, and culturally appropriate patient education programs determine the pace of adoption. As such, regional strategies must integrate tailored value propositions, local stakeholder engagement, and flexible commercial models to navigate distinct healthcare landscapes effectively.

Competitive landscape shaped by legacy device manufacturers, software-first entrants, and outcome-driven service models that redefine value across therapy lifecycles

Competitive dynamics reflect a blend of established medical device firms, emerging technology entrants, and specialized component suppliers collaborating to advance continuous infusion capabilities. Incumbent manufacturers leverage deep clinical relationships, regulatory experience, and broad distribution networks to maintain market presence, while newer entrants frequently emphasize software innovation, user experience, and niche form factors to capture specific patient segments. Strategic alliances between device makers and digital health vendors accelerate feature integration, particularly around closed-loop compatibility and data analytics services.

Investments in intellectual property around infusion algorithms, sensor interoperability, and cybersecurity represent strategic priorities, as stakeholders seek to protect differentiating features while enabling controlled interoperability. At the same time, service-oriented business models-such as bundled devices with remote monitoring subscriptions or integrated training and adherence programs-gain traction, creating recurring revenue streams and enhanced patient engagement. Procurement and hospital sourcing teams increasingly evaluate total cost of ownership alongside clinical outcomes, which encourages vendors to demonstrate longitudinal value through real-world evidence and post-market studies.

Looking ahead, competitive advantage will accrue to organizations that combine regulatory agility, robust quality and supply systems, and a clear product-service strategy that supports clinicians and patients through the entire therapy lifecycle. Collaboration with payers, providers, and patient groups will further distinguish vendors able to translate technical features into measurable care improvements.

Prioritize interoperability, supply diversification, real-world evidence, and human-centered design to strengthen resilience and accelerate adoption across care settings

Industry leaders should prioritize a strategic agenda that aligns product innovation with clinical integration, supply chain resilience, and payer engagement to preserve sustainability and accelerate adoption. First, invest in interoperable platforms and validated algorithms that enable meaningful data exchange with glucose monitoring systems and electronic health records; this foundation supports clinician workflows and enhances the clinical utility of therapy data. Second, diversify manufacturing and sourcing strategies to reduce exposure to trade policy volatility and component shortages while accelerating time to recovery in the event of disruption.

Third, build evidence-generation programs that go beyond controlled trials to include real-world studies, health economic analyses, and patient-reported outcomes; these data strengthen reimbursement conversations and inform iterative design improvements. Fourth, tailor commercial models to regional payer landscapes and end-user needs by offering flexible purchasing options, service bundles, and clinician training that lower barriers to adoption. Fifth, embed human-centered design principles to ensure devices meet the cognitive, sensory, and lifestyle needs of varied age groups, thereby improving adherence and satisfaction.

Finally, cultivate multi-stakeholder partnerships spanning clinicians, payers, patient advocacy groups, and technology partners to co-create solutions that align clinical efficacy with practical implementation. By executing this multipronged strategy, industry leaders will enhance resilience, foster differentiated value, and deliver improved outcomes for patients and care teams alike.

A transparent mixed-methods research framework combining stakeholder interviews, clinical literature synthesis, and supply chain analysis to produce actionable device and commercial insights

The research approach integrates qualitative and quantitative methods to ensure comprehensive insight into device performance, stakeholder perspectives, and operational constraints. Primary research included structured interviews with clinicians, procurement officers, and patient advocates to capture firsthand experience with device usability, clinical workflow integration, and real-world adherence challenges. These conversations informed thematic analysis that highlights common pain points and opportunity areas related to connectivity, dosing flexibility, and caregiver support.

Secondary research synthesized publicly available regulatory guidance, clinical literature, and technical standards to contextualize product design and approval considerations. Where applicable, technical white papers and peer-reviewed clinical studies supported assessments of algorithmic approaches and safety considerations. Supply chain and trade policy impacts were analyzed using trade flow data, procurement publications, and supplier disclosures to develop a pragmatic view of operational vulnerabilities and mitigation levers.

Finally, cross-validation exercises reconciled primary insights with secondary sources to increase confidence in thematic findings and recommendations. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, and it supports actionable conclusions for product development, commercialization, and strategic planning while acknowledging regional variability and evolving regulatory expectations.

An integrated strategy combining interoperable technology, operational agility, and targeted evidence generation will determine long-term success in infusion therapy

Continuous subcutaneous insulin infusion stands at an inflection point where technological maturation, shifting care models, and global policy dynamics converge to create both promise and complexity. Devices that marry robust safety engineering with seamless data integration and human-centered usability will meet clinician and patient expectations more effectively. At the same time, supply chain agility and regulatory foresight are crucial to navigate evolving trade and compliance landscapes without interrupting patient access.

The interplay between device form factor, insulin pharmacology, patient age-related needs, and care setting requirements underscores the importance of nuanced product portfolios and targeted clinical engagement. Moreover, competitive advantage will favor organizations that can translate technical differentiation into verifiable clinical and economic benefits. In conclusion, stakeholders who adopt an integrated strategy-combining interoperable technology, diversified operations, strong evidence generation, and tailored regional approaches-will be best positioned to deliver meaningful improvements in diabetes management and to sustain long-term growth in a dynamic therapeutic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring data with advanced insulin pump algorithms enabling predictive insulin dosing adjustments in hybrid closed-loop systems
  • 5.2. Development of tubeless patch pumps with smartphone connectivity and remote patient monitoring capabilities for enhanced adherence
  • 5.3. Adoption of ultra-rapid-acting insulin formulations compatible with insulin pump therapy to improve postprandial glucose control
  • 5.4. Implementation of artificial intelligence and machine learning models for personalized insulin delivery based on real-time lifestyle data
  • 5.5. Expansion of reimbursement frameworks and digital health ecosystems to support telehealth initiation and management of insulin pump therapy
  • 5.6. Collaboration between pharmaceutical companies and medical device manufacturers to co-develop interoperable closed-loop insulin delivery solutions
  • 5.7. Surging demand for pediatric insulin pump systems featuring simplified user interfaces and customizable settings for young patients
  • 5.8. Emergence of disposable patch pump systems with extended wear duration to reduce device maintenance burden for users

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Subcutaneous Insulin Infusion Market, by Product Type

  • 8.1. Conventional
    • 8.1.1. Electronics Based Pumps
    • 8.1.2. Mechanical Pumps
  • 8.2. Patch

9. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type

  • 9.1. Rapid Acting Analog
  • 9.2. Regular Insulin
  • 9.3. Short Acting

10. Continuous Subcutaneous Insulin Infusion Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Continuous Subcutaneous Insulin Infusion Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Homecare
  • 11.3. Hospitals

12. Continuous Subcutaneous Insulin Infusion Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Continuous Subcutaneous Insulin Infusion Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Continuous Subcutaneous Insulin Infusion Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic PLC
    • 15.3.2. Insulet Corporation
    • 15.3.3. Tandem Diabetes Care, Inc.
    • 15.3.4. Roche Diabetes Care AG
    • 15.3.5. Ypsomed AG
    • 15.3.6. Sooil Development Co., Ltd.
    • 15.3.7. Medtrum Technologies, Inc.
    • 15.3.8. Bigfoot Biomedical, Inc.
    • 15.3.9. B. Braun SE
    • 15.3.10. Baxter International, Inc.
    • 15.3.11. Becton, Dickinson and Company
    • 15.3.12. MicroPort Scientific Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 246. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 247. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 258. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 259. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 281. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA CONTINUOUS SUBC